Drug
Nbib 0000223
Nbib 0000223: highest development phase Phase 1, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBIB-0000223 NCT07934303 | Phase 1 | Friedreich's Ataxia |
Latest
No recent events.
Follow Nbib 0000223 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.